| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst John Sourbeer maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $320 to...
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target fro...
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the ...
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp...
West Pharmaceutical posts Q3 earnings of $1.96 per share and raises 2025 guidance, driven by GLP-1 demand and strong HVP compon...
West Pharmaceutical Servs (NYSE:WST) raises FY2025 Adj EPS guidance from $6.65-$6.85 to $7.06-$7.11 vs $6.77 analyst estimate. ...
West Pharmaceutical Servs (NYSE:WST) raises FY2025 GAAP EPS guidance from $6.36-$6.56 to $6.75-$6.80 vs $6.53 analyst estimate..